G. Fyfe - Concepedia

Author

G. Fyfe

National Institute of Allergy and Infectious Diseases

Also Known As

G A Fyfe, G Fyfe, G. A. Fyfe, G. Fyfe, Gwendolyn A. Fyfe, Gwendolyn Anne Fyfe, Gwendolyn Fyfe

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases Duke University Sarah Cannon Kaiser Permanente National Institutes of Health

About

G. Fyfe is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	311
2	Immunology	5	5	255
3	Pathology	3	3	112
4	Allergy	1	1	44
5	Cell Biology	1	1	44

G. Fyfe

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. G. Fyfe, Richard I. Fisher, S A Rosenberg, Journal of Clinical Oncology	1995	1.4K
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Richard I. Fisher, Steven A. Rosenberg, G. Fyfe PubMed	2000	441
Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus Joseph A. Kovacs, Susan Vogel, Jeffrey M. Albert, New England Journal of Medicine	1996	408
Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data Kim Margolin, Michael Gordon, Eric Holmgren, Journal of Clinical Oncology	2001	366
Subcutaneous Administration of Interleukin‐2 in Human Immunodeficiency Virus Type 1—Infected Persons Richard T. Davey, Doreen Chaitt, Stephen C. Piscitelli, The Journal of Infectious Diseases	1997	166
A Randomized Trial of High‐ versus Low‐Dose Subcutaneous Interleukin‐2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection Richard T. Davey, Doreen Chaitt, Jeffrey M. Albert, The Journal of Infectious Diseases Primary ImmunodeficiencyTranslational MedicineHuman Immunodeficiency VirusTreatment And PreventionHuman Retrovirus	1999	135
Outpatient Continuous Intravenous Interleukin‐2 or Subcutaneous, Polyethylene Glycol‐Modified Interleukin‐2 in Human Immunodeficiency Virus‐Infected Patients: A Randomized, Controlled, Multicenter Study Andrew Carr, Sean Emery, Andrew R. Lloyd, The Journal of Infectious Diseases	1998	93
Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity ZP Bernstein, MM Porter, M. Gould, Blood	1995	93
High-dose aldesleukin in renal cell carcinoma: long-term survival update. Richard I. Fisher, Saul A. Rosenberg, Mario Sznol, PubMed	1997	92
Beh?et syndrome Arthur J. Ammann, Alan J. Johnson, G. Fyfe, The Journal of Pediatrics	1985	71

Page 1